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Background: Haptoglobin genotypes, and interleukin-6 and -8 participate in the pathophysi-
ology of sickle cell anemia. The expression of cytokines is regulated by genetic mechanisms
however the effect of haptoglobin polymorphisms on these cytokines is not fully understood.
This study aimed to compare the frequency of haptoglobin genotypes and the interleukin-6
and -8 concentrations in sickle cell anemia patients and controls to investigate the associ-
ation  between haptoglobin genotypes and cytokine levels.
Methods: Sixty sickle cell anemia patients and 74 healthy individuals were analyzed. Hap-
toglobin genotypes were determined by multiplex polymerase chain reaction, and the
interleukin-6 and -8 levels by enzyme linked immunosorbent assay. The association between
haptoglobin genotypes and cytokines was investigated by statistical tests.
Results: Hp2-1 was the most common genotype in both the cases and controls while Hp1-
1  was less frequent among sickle cell anemia patients. Interleukin-6 and -8 levels were
higher in patients than controls (p-value <0.0001). There was no signiﬁcant difference in
interleukin-6 and -8 concentrations between the genotypes (p-value >0.05). A similar trend
was  observed among the controls.
Conclusion: Although, levels of interleukin-6 and -8 were higher in the sickle cell anemia
patients, they appeared not to be related to the haptoglobin genotypes. Further investiga-
tions are necessary to identify factors responsible for increased secretion of the interleukin-6
and -8 pro-inﬂammatory cytokines in patients with sickle cell anemia.©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
of affected individuals is about 7.2 million. Sickle hemoglobinntroductionickle cell anemia (SCA) is the most common hereditary
onogenic disease in Brazil, where the prevalence of the trait
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in the general population is 2–8% and the estimated number
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 04037-002 São Paulo, SP, Brazil.
(Hb S) is caused by a mutation of a single nucleotide (HBB
glu(E)6Val(A); GAG>GTG; rs334; HBB:c.20A>T; MIM: #603903)2
in the beta globin gene, which results in glutamic acid being
 e Terapia Celular. Published by Elsevier Editora Ltda. All rights
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substituted by valine at position 6 of the beta globin chain.
This change leads to Hb S polymerization, especially under
low oxygen tension.3
Patients with SCA suffer from acute and chronic vascular
occlusion due to polymerization of Hb S in red cells. Vascular
occlusion is a major pathophysiologic event in SCA, leading
to variety of morbidities such as painful crisis, acute chest
syndrome, stroke, aseptic necrosis of bones, priapism, leg
ulcers and proliferative retinopathy. Patients also experience
chronic hemolytic anemia, inﬂammation, cell adhesion, tissue
hypoxia, organ ischemia and tissue infarction.4
Hemolytic anemia, a major complication of SCA is linked
to reduced nitric oxide (NO) bioavailability. In normal condi-
tions, NO binds to soluble guanylate cyclase, which converts
guanosine triphosphate to cyclic guanosine monophosphate.
It causes relaxation of vascular smooth muscle and eventual
peripheral vasodilatation. Plasma hemoglobin released from
intravascular hemolysis of sickled red cells consumes NO and
impairs its homeostatic vascular functions. Apart from the
scavenging effects of cell-free plasma Hb on NO, reactive oxy-
gen species (ROS) also scavenge NO and deplete its pool. The
generation of ROS in patients with sickle cell disease (SCD)
results from tissue ischemia that occurs during vaso-occlusion
and the accompanying ischemia-reperfusion injury.5 It has
also been suggested that the plasma level of l-arginine, a
precursor of NO, is depleted during severe hemolysis, vaso-
occlusive crises and acute chest syndrome. This depletion is
partly due to increased levels of plasma arginase in these con-
ditions, especially during severe hemolysis.6
Increased expression of adhesion molecules, including
interleukin (IL)-6 also stimulates the adherence of red cells
and neutrophils to the endothelium.4,7 IL-6, a multifunctional
cytokine, plays a strategic role in host defense and exhibits
both pro-inﬂammatory and anti-inﬂammatory properties. It is
encoded by the IL-6 gene which is located on chromosome 7 at
7p21-p14, between D75135 and D75370.8 Apart from stimula-
tion of B cell proliferation into plasma cells, its other biological
activities include induction of the secretion of acute phase
proteins by liver cells, T-cell activation and differentiation into
cytotoxic cells, and activation of hematopoiesis.9
Several studies have shown that the levels of cytokines in
patients with SCA, even in steady state, are elevated.10–13 In
individuals with SCA, pro-inﬂammatory cytokines such as IL-
1, IL-6, IL-8 and tumor necrosis factor alpha (TNF-)  cause
chronic endothelium activation and adhesion of sickled red
cells, and are thus responsible for the constant local tissue
ischemia and necrosis seen. In addition, there is increased
leukocyte aggregation in response to inﬂammatory cytokines
in SCA.10
The primary mechanism of defense against the deleterious
effects of free Hb is provided by haptoglobin (Hp), an acute
phase 2-globulin glycoprotein and important physiologic
antioxidant, which binds to plasma Hb forming a soluble com-
plex (Hb-Hp complex) to eliminate Hb from the plasma. This
clearance is important because the complex is not inert and
can catalyze oxygen reactive species and consume NO.14–16The Hp locus in the chromosome, 16q22, is polymorphic.
Two classes of alleles have been identiﬁed: 1 and 2, and the
Hp-2 allele presents a duplicated DNA segment of 1700 base
pairs (bp) due to an intragenic duplication of exons 3 and 2 0 1 5;3  7(5):329–335
4.17,18 In South America and Africa, the Hp-1 allele predom-
inates, unlike in Southeast Asia where the frequency of the
Hp-1 allele is lower than the Hp-2 allele.19 There are three pos-
sible genotypes for the Hp in humans: Hp 1-1, Hp 2-1 and Hp
2-2.
These phenotypes differ in the structure of the protein,
electrophoretic mobility, antioxidant and anti-inﬂammatory
properties, hence they exhibit different clinical effects.18,20,21
Hp 1-1 is the most biologically active in binding free Hb and
suppressing consequent inﬂammatory responses. Hp 2-2 is the
least biologically active with a reduced overall activity and Hb
clearance effects, while Hp 2-1 is intermediate.14 Hp signiﬁ-
cantly reduces the synthesis of ROS in individuals with the Hp
1-1 genotype because of its potent antioxidant activity, but in
people with the Hp 2-2 polymorphism, the antioxidant activity
is weak which ultimately favors the persistence of inﬂamma-
tory response.22,23 Guetta et al. and Uskokovic et al. reported
that the Hp 1 allele when bound to free Hb, stimulates the
secretion of IL-6 and IL-10 more  signiﬁcantly than the Hp 2
allele.14,24
In patients with SCA, a disease characterized by both
chronic and acute inﬂammatory and hemolytic states, the
modulatory role of the Hp genotype on the expression of these
cytokines is still largely understudied. The present study was
therefore designed to investigate the association between the
different Hp polymorphisms and the secretion of IL-6 and IL-8
in Brazilian SCA patients in comparison to healthy individuals
from the same locality.
Methods
Cases  and  controls
This case control study included 60 patients with SCA, aged
13 years and above, who were recruited from the Hereditary
Anemia Outpatient Clinic of the Hematology and Blood Trans-
fusion Unit, Universidade Federal de São Paulo (UNIFESP),
Brazil. At the time of recruitment, all the patients were in
steady state, that is, they had had no acute event for at least
twelve consecutive weeks. The control group consisted of 74
apparently healthy, age and gender-matched Hb AA volun-
teers from the same locality.
Pregnant women, individuals with acute or chronic infec-
tions, chronic renal impairment, rheumatologic disorders,
patients on hydroxyurea therapy, chronic blood transfusion
therapy and those who had had a blood transfusion within
the preceding three months were excluded from the study. All
participants or their parents/guardians (in the cases of ado-
lescents) gave written informed consent before participation
in the study. Moreover, permission for the study was obtained
from the Research Ethics Committee of the institution.
Sociodemographic characteristics of the study participants
were obtained using a structured questionnaire while data on
SCA complications were retrieved from medical charts.Determination  of  plasma  level  of  cytokines
Whole blood samples were collected from antecubital veins
under minimal tourniquet pressure. The plasma levels
of IL-6 and IL-8 were determined using high sensitivity
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nzyme linked immunosorbent assays (ELISA) according to
he instructions provided by the manufacturer. The IL-6 ELISA
BD OptEIA, BD Biosciences, San Diego, USA) had a normal
ange 2.2–12.1 pg/mL and limit of detection of 2.2 pg/mL. For
he IL-8 ELISA (BD OptEIA, BD Biosciences, San Diego, USA), the
ormal range was 10.2–34.3 pg/mL and the limit of detection
as 0.8 pg/mL.
NA  extraction
uffy-coat samples, which were stored at −80 ◦C at the
olecular Biology Laboratory of UNIFESP, were defrosted and
ubjected to red blood cell lysis with saponin. Leukocytes
ere washed with Solution A (100 mM KCl, 10 mM Tris and
.5 mM MgCl2). DNA extraction was carried out using Solu-
ion A without saponin and Solution B (10 mM Tris, 2.5 mM
gCl2, 1% Tween-20, 1% Triton ×100 and proteinase K). After
ne-hour incubation at 60 ◦C, DNA was puriﬁed with Phe-
ol:chloroform:isoamyl alcohol (25:24:1).25
aptoglobin  genotyping
p genotyping was performed by a polymerase chain reac-
ion (PCR) technique as described by Koch et al. in 2002.17
he method consists of two protocols. In protocol 1, the
757 bp allele 1 speciﬁc sequence and the 3481 bp allele 2 spe-
iﬁc sequence were ampliﬁed. In homozygous individuals, the
ntensity of the 1757 bp allele-1 speciﬁc band is higher than the
481 bp allele-2 speciﬁc band. For 22 patients with SCA, it was
ot possible to deﬁne conclusively whether the 3481 bp band
as present. These samples were submitted to protocol 2 in
rder to amplify the 349 bp allele-2 speciﬁc sequence. Proto-
ol 2 involved the ampliﬁcation of the 349 bp allele 2 speciﬁc
equence to conﬁrm when the result of the ﬁrst assay was not
Table 1 – Sociodemographic, haptoglobin genotypes and plasm
anemia patients and controls.
Variables SCA group
n = 60
Gender – n (%)
Male 32 (53) 
Female 28 (47) 
Age – years
Median 26.00 
Range 15–50 
Plasma IL (pg/mL) – mean ± SD
IL-6 15.9 ± 9.1 
IL-8 20.5 ± 15.2 
Haptoglobin alleles – n (%)
Hp-1 54 (45.0) 
Hp-2 66 (55.0) 
Haptoglobin genotypes – n (%)
Hp 1-1 10 (16.7) 
Hp 2-1 34 (56.7) 
Hp 2-2 16 (26.6) 
SCA: sickle cell anemia; SD: standard deviation, IL: interleukin.
a Chi-square.
b Mann–Whitney test.
c Independent sample t-test. 1 5;3  7(5):329–335 331
conclusive. The PCR products were separated by agarose gel
electrophoresis.
Statistical  analysis
Data was analyzed using the Statistical Package for the Social
Sciences (SPSS) computer program version 17.0. The mean
plasma values of the interleukins were compared between
cases and control by the independent sample t-test, while IL
values between the HP 1-1, Hp 2-1 and Hp 2-2 genotypes were
compared with analysis of variance (ANOVA). The frequencies
of Hp polymorphisms in the patients and the controls were
compared with the chi-square test. Statistical signiﬁcance was
set for p-values <0.05.
Results
As shown in Table 1, the age and gender proﬁles were similar
between SCA patients and the control group.
Interleukin-6  and  -8  plasma  levels
The plasma levels of IL-6 and IL-8 were signiﬁcantly higher in
patients compared to the controls (p-value <0.0001) as shown
in Table 1. There was about a four-fold increase in the levels
of the plasma IL-6 and IL-8 in patients with SCA compared to
the healthy controls.Haptoglobin  alleles  and  genotypes
The frequencies of Hp-1 alleles among the cases and con-
trols were 54 (45.0%) and 81 (54.7%) respectively (Table 1). Hp
a levels of interleukin-6 and -8 between the sickle cell
Control  group
n = 74
p-value
39 (53) 1.00a
35 (47)
29.00 0.29b
17–60
4.4 ± 7.4 <0.0001c
4.9 ± 7.4 <0.0001c
81 (54.7) 0.113a
67 (43.5)
25 (33.8)
31 (41.9) 0.07a
18 (24.3)
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Table 2 – Hematological proﬁle of the 60 sickle cell patients.
Hematological parameters Overall
Mean (SD)
Hp  1-1
Mean (SD)
Hp  1-2
Mean (SD)
Hp  2-2
Mean (SD)
F  test p-valuea
Hemoglobin (g/dL) 8.1 (1.0) 7.7 (0.9) 8.3 (1.0) 8.0 (1.2) 1.143 0.326
Hematocrit (%) 23.4 (3.1) 21.9 (2.2) 23.9 (3.2) 23.2 (3.0) 1.643 0.202
MCV (fL) 91.6 (8.2) 89.8 (8.2) 92.9 (6.9) 89.8 (10.3) 1.081 0.346
Leukocyte count (×1009/L) 11.2 (2.8) 11.1 (2.1) 11.4 (3.0) 10.9 (2.6) 0.146 0.865
Platelet count (×1009/L) 428.4 (143.0) 482.5 (158.5) 403.8 (143.8) 446.9 (127.2) 1.368 0.263
Reticulocyte count (×1009/L) 190.4 (134.0) 196.9 (114.4) 204.5 (113.7) 156.9 (180.9) 0.643 0.530
Hemoglobin F (%) 7.5 (6.2) 8.6 (6.1) 8.0 (6.7) 5.5 (4.9) 0.970 0.386
meteMCV: mean corpuscular volume.
a ANOVA was used to compare the means of the hematological para
2-1 was the most common Hp genotype in cases and con-
trols, accounting for 34 (56.7%) and 31 (41.9%) respectively. The
least common genotype in SCA patients was Hp 1-1, 16.7%.
There was no statistically signiﬁcant difference in the fre-
quency distribution of Hp genotypes between cases and the
controls [2 = 5.280, degree of freedom (df) = 2, p-value = 0.07].
The mean values of all the hematological parameters were not
signiﬁcantly different between the three Hp genotype groups
(Table 2).
Association  between  haptoglobin  genotypes  and
interleukin-6
Table 3 compares the mean plasma concentrations of IL-6 of
the three Hp genotypes. For the cases, there was no signiﬁcant
Table 3 – Association between haptoglobin genotypes and plas
IL-6 concentration (pg/mL) Hp1-1 
Patients
Mean 14.6 
Standard deviation 3.2 
Median 14.7 
Range 10.0–20.9 
Controls
Mean 2.5 
Standard deviation 1.5 
Median 2.2 
Range 2.2–9.5 
p-value <0.0001a
IL-8 concentration (pg/mL) Hp1-1 
Patients
Mean 20.1 
Standard deviation 10.5 
Median 18.3 
Range 2.6–38.9 
Controls
Mean 4.8 
Standard deviation 5.9 
Median 2.7 
Range 0.8–19.6 
p-value 0.0002a
IL: Interleukin.
a Independent sample t-test was used to compare the mean interleukin c
b ANOVA was used to compare the mean interleukin concentrations betwrs between the three Hp genotypes.
difference in the mean plasma concentrations of IL-6 for the
Hp 1-1, Hp 2-1 and Hp 2-2 genotypes (14.6; 16.5 and 15.4 pg/mL,
respectively; F = 84.47; p-value = 0.54). For the controls, the dif-
ference in the mean plasma concentrations of IL-6 for the Hp
genotype groups was also similar (F = 53.23; p-value = 0.161).
Two-thirds of patients with SCA, comprising of 8 with Hp
1-1; 20 with Hp 2-1 and 12 with Hp 2-2 had high levels of IL-
6 i.e. IL-6 >12.1 pg/mL, while only two (3.3%) had low levels
(values <2.2 pg/mL) (Table 4). However, among the controls, the
majority, 62 (83.8%) had low levels of IL-6.Haptoglobin  genotypes  and  interleukin-8
Furthermore, the mean plasma values of IL-8 of the three Hp
genotypes were similar both for the cases and the controls
ma concentrations of interleukin-6 and -8 levels.
Hp1-2 Hp2-2 p-value
16.5 15.4 0.538b
11.0 6.9
13.4 15.3
2.2–53.8 2.2–30.4
4.6 6.8 0.161b
8.5 9.5
2.2 2.2
2.2–48.5 2.1–32.1
<0.0001a 0.0061a
Hp1-2 Hp2-2 p-value
19.2 23.5 0.522b
14.5 19.1
16.6 17.7
1.4–53.5 1.6–68.3
5.7 3.5 0.606b
9.0 6.7
1.1 1.0
0.3–37.5 0.1–28.5
<0.0001a <0.0001a
oncentrations between the patients and the controls.
een the three Hp genotypes.
rev bras hematol hemoter. 2 0 1 5;3  7(5):329–335 333
Table 4 – Relationship between haptoglobin genotypes and interleukin-6 and -8 levels.
Haptoglobin genotype Hp 1-1 Hp 2-1 Hp 2-2 Total
n (%) n (%) n (%) n (%)
IL-6 in SCA group (n = 60)
High level (>12.1 pg/mL) 8 (80.0) 20 (58.8) 12 (75.0) 40 (66.7)
Normal level (2.2–12.1 pg/mL) 2 (20.0) 13 (38.2) 3 (18.8) 18 (30.0)
Low level (<2.2 pg/mL) 0 (0) 1 (2.9) 1 (6.2) 2 (3.3)
IL-6 in Control group (n = 74)
High level (>12.1 pg/mL) 0 (0) 1 (3.2) 4 (22.2) 5 (6.7)
Normal level (2.2–12.1 pg/mL) 2 (8.7) 4 (12.9) 1 (5.6) 7 (9.5)
Low level (<2.2 pg/mL) 23 (91.3) 26 (83.9) 13 (72.2) 62 (83.8)
IL-8 in SCA group (n = 60)
High level (>34.3 pg/mL) 1 (10.0) 6 (17.6) 4 (25.0) 11 (18.3)
Normal level (10.2–34.3 pg/mL) 7 (70.0) 17 (50.0) 10 (62.5) 34 (56.7)
Low level (0.8–10.1 pg/mL) 2 (20.0) 11 (32.4) 2 (12.5) 15 (25.0)
Extremely low level (<0.8 pg/mL) 0 (0) 0 (0) 0 (0) 0 (0)
IL-8 in Control group (n = 74)
High level (>34.3 pg/mL) 0 (0) 0 (0) 0 (0) 0 (0)
Normal level (10.2–34.3 pg/mL) 4 (16.0) 5 (16.1) 1 (5.6) 10 (13.5)
Low level (0.8–10.1 g/mL) 12 (48.0) 14 (45.2) 8 (44.4) 34 (46.0)
Extremely low level (<0.8 pg/mL) 9 (36.0) 12 (38.7) 9 (50.0) 30 (40.5)
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F = 97.34; p-value = 0.52 and F = 56.82; p-value = 0.61, respec-
ively) (Table 3).
As shown in Table 4, the majority of the cases (56.7%) as
ell as the controls (46.0%) had normal levels of plasma IL-8.
iscussion
CA is a monogenic disease with an exceptional phenotypic
ariability that is regulated by several known and unknown
enetic factors. Understanding the vascular and inﬂammatory
omponents of the disease can help in providing information
n the possible genomic sites that inﬂuence the phenotype.
tudies on the Hp polymorphisms, an important marker of
ascular disease and pro-inﬂammatory cytokines may there-
ore provide useful information. To the best knowledge of the
uthors, this is the ﬁrst study that examined the relationship
etween Hp polymorphisms and interleukins among Brazilian
CA patients. The ability to predict the phenotype of SCA dur-
ng the ﬁrst months of life or even in the prenatal period will
llow a more  precise prognosis and individualized treatment.
Intravascular hemolysis produces a state of endothe-
ial dysfunction, vascular proliferation, inﬂammation and
xidative stress. Recent studies have demonstrated the impor-
ant roles of free plasma Hb in reducing NO. Intravascular
emolysis and the reduction of NO causes increased expres-
ion of endothelin-1, and activation of endothelial adhesion
olecules and platelets. Thus, not only do they cause vaso-
onstriction, but NO is involved in endothelial activation and
roliferation that eventually contributes to the pathogenesis
f SCA.4,26 It is known that sickled red cells bind to the vascular
ndothelium cells by integrin alpha-4 beta-1. This membrane
rotein then acts as a receptor for either ﬁbronectin or VCAM-
. In the endothelium, VCAM-1 is stimulated by inﬂammatory
ytokines, such as IL-6 and IL-8 which are released by the acti-
ated leucocytes.27,28 Heme and hemin, which are releasedinto the circulation during the active phase of sickle-cell dis-
ease, also contribute to inﬂammatory states in individuals
with SCA by increasing the expression of endothelial adhe-
sion molecules and adherence of leukocytes and reticulocytes
to endothelial cells.29
In the present study, higher levels of both IL-6 and IL-8 were
detected in SCA individuals compared to the control group
(p-value <0.001). Our data agree with previous studies that
identiﬁed elevated levels of inﬂammatory cytokines in SCA
patients.10,30,31
Considering that the transcription of cytokines is regu-
lated by a great number of genetic mechanisms, this study
intended to verify whether the Hp polymorphisms inﬂuence
cytokine secretion. Hp has emerged as one of the most impor-
tant SCD phenotypic modulators, as it is a protein with high
capability to bind to free Hb in the plasma, forming the Hp–Hb
complex and thereby preventing heme-catalyzed oxidative
damage.32 Although the three Hp phenotypes have the same
ability to bind to free Hb, the speed of heme release can be
related to differences in their molecular size. Hp 2-2, which
is a more  complex polypeptide, removes iron more  slowly to
the extravascular space thereby allowing free Hb to be in the
circulation for a longer period, causing more  oxidative stress.
On the other hand, Hp 1-1 protects the endothelium against
oxidative damage, as it is the most biologically active.33 In
this analysis, the Hp 2-1 phenotype was more  common in
both patients and controls (56.7% and 41.9%, respectively).
Moreover, the proﬁle of the Hp genotype was not different
between the groups (p-value = 0.70). This pattern agrees with
most studies on the distribution of haplotype polymorphisms
in SCD.32,34
Besides its antioxidant properties, Hp is an acute phase
protein with immune-modulatory functions. It modulates
the equilibrium between Th1 and Th2 lymphocytes by pre-
dominantly promoting Th1 cellular response. These cells
are more  effective in protecting against infections involving
oter.
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intracellular parasites and inhibiting the Th2 cytokines
needed for humoral response.35 Moreover, the Hp-1-1-Hb com-
plex signiﬁcantly stimulates the secretion of more  IL-6 than
the Hp-2-2-Hb complex.14
There have been inconsistencies in the distribution of Hp
genotypes in the SCA population. In 2011, Santos et al.32
reported that the Hp 2-2 phenotype in Brazilian SCA patients
was less frequent than the Hp 1-1 phenotype and hypothe-
sized that Hp 2-2 might be associated with worse prognosis
because of lower antioxidant capacity and higher inﬂamma-
tory response. In the current study, the Hp 1-1 phenotype
was less common (16.7%), which agrees with the ﬁndings of
Adekile & Haider in Kuwaiti patients with SCD in which only
4.9% had Hp 1-1 compared to 52.4% in those with the Hp 2-2
genotype.34 On the contrary, in the same study they reported
Hp 2-2 as being less frequent among Nigerian patients with
SCD. It was concluded that, in SCD individuals, the Hp geno-
types appear to differ between ethnic groups and geographical
areas, and are not necessarily linked to -globin gene haplo-
types in different populations.
Most studies on the inﬂuence of Hp polymorphisms on the
clinical phenotypes of SCD have failed to establish any strong
link between the two. For instance, no signiﬁcant association
was found between the Hp-2 allele and increased risk of severe
vaso-occlusive crises among Kuwaiti Hb SS patients.34 This
may imply that other factors mediate the inﬂuence of Hp.
Of such, the scavenger receptor CD163 and heme oxygenase
play active roles in the clearance of the Hb–Hp complex from
the plasma, thereby preventing oxidative damage caused by
heme.15 The level and activity of CD163, rather than Hp poly-
morphisms may therefore be related to SCD complications
and severity.
Among the SCA patients in the present study, the geno-
types did not appear to be related to the serum levels of IL-6
and IL-8; there was no relationship between the Hp geno-
types and cytokine levels. This is in contrast to the ﬁndings
of Guetta et al. who reported that the Hp-1 allele was asso-
ciated with the secretion of signiﬁcantly more  IL-6 and IL-10
than the Hp-2 allele.14 They also demonstrated that the release
of these cytokines was dependent on the binding of the Hb-
Hp complex to the CD163 receptor and the activity of casein
kinase II. However, the lack of association of Hp polymor-
phisms with the expression of pro-inﬂammatory cytokines
may be due to the small number of patients in the present
study.
Considering the important roles of cytokines in SCA patho-
physiology, further investigations are necessary to identify
factors that are responsible for increased secretion of plasma
IL-6 and IL-8. Although the results of this study do not allow
us to conclude that Hp genotypes on their own inﬂuence
expression of IL-6 and 8 in SCA patients, this polymorphism
when investigated with other genetic factors, may unravel
the pathogenesis of elevated pro-inﬂammatory cytokines in
SCA.Conﬂicts  of  interest
The authors declare no conﬂicts of interest.
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